MX345185B - GOLD NANOPARTICLES RADIOLABELLED WITH 177LU AND CONJUGATED TO PEPTIDES C (RGDFK) C AS A NOVEL RADIOPHARMACEUTICAL FOR THE THERAPY OF TUMORS OVER-EXPRESSING INTEGRINS A (V) ß (3). - Google Patents

GOLD NANOPARTICLES RADIOLABELLED WITH 177LU AND CONJUGATED TO PEPTIDES C (RGDFK) C AS A NOVEL RADIOPHARMACEUTICAL FOR THE THERAPY OF TUMORS OVER-EXPRESSING INTEGRINS A (V) ß (3).

Info

Publication number
MX345185B
MX345185B MX2012003632A MX2012003632A MX345185B MX 345185 B MX345185 B MX 345185B MX 2012003632 A MX2012003632 A MX 2012003632A MX 2012003632 A MX2012003632 A MX 2012003632A MX 345185 B MX345185 B MX 345185B
Authority
MX
Mexico
Prior art keywords
radiopharmaceutical
rgdfk
peptides
conjugated
gold nanoparticles
Prior art date
Application number
MX2012003632A
Other languages
Spanish (es)
Other versions
MX2012003632A (en
Inventor
Ferro Flores Guillermina
Alejandra Luna Gutiérrez Myrna
Elí Ocampo García Blanca
Morales Avila Enrique
Patricia Jiménez Mancilla Nallely
Original Assignee
Inst Nac De Investig Nucleares
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nac De Investig Nucleares filed Critical Inst Nac De Investig Nucleares
Priority to MX2012003632A priority Critical patent/MX345185B/en
Publication of MX2012003632A publication Critical patent/MX2012003632A/en
Publication of MX345185B publication Critical patent/MX345185B/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention refers to a novel heterofunctional, multimeric and multivalent radiopharmaceutical of gold nanoparticles, which are multilabelled with lutetium-177 (177Lu) and conjugated to hundreds of cyclo peptides (Arg-Gly-Asp-D-Phe) Cys (c(RGDfk)C) as an agent for the radiotherapy of aggressive tumours of quick growth and metastasis as breast cancer and glioblastoma, by techniques of molecular image in nuclear medicine. The purpose of the present invention is to provide a novel specific radiopharmaceutical (molecular target radiopharmaceutical) for providing radiotherapy to tumours over-expressing integrins a(v) ß(3), which is totally different from those currently available on the market.
MX2012003632A 2012-03-27 2012-03-27 GOLD NANOPARTICLES RADIOLABELLED WITH 177LU AND CONJUGATED TO PEPTIDES C (RGDFK) C AS A NOVEL RADIOPHARMACEUTICAL FOR THE THERAPY OF TUMORS OVER-EXPRESSING INTEGRINS A (V) ß (3). MX345185B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2012003632A MX345185B (en) 2012-03-27 2012-03-27 GOLD NANOPARTICLES RADIOLABELLED WITH 177LU AND CONJUGATED TO PEPTIDES C (RGDFK) C AS A NOVEL RADIOPHARMACEUTICAL FOR THE THERAPY OF TUMORS OVER-EXPRESSING INTEGRINS A (V) ß (3).

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2012003632A MX345185B (en) 2012-03-27 2012-03-27 GOLD NANOPARTICLES RADIOLABELLED WITH 177LU AND CONJUGATED TO PEPTIDES C (RGDFK) C AS A NOVEL RADIOPHARMACEUTICAL FOR THE THERAPY OF TUMORS OVER-EXPRESSING INTEGRINS A (V) ß (3).

Publications (2)

Publication Number Publication Date
MX2012003632A MX2012003632A (en) 2013-09-26
MX345185B true MX345185B (en) 2017-01-20

Family

ID=49684370

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003632A MX345185B (en) 2012-03-27 2012-03-27 GOLD NANOPARTICLES RADIOLABELLED WITH 177LU AND CONJUGATED TO PEPTIDES C (RGDFK) C AS A NOVEL RADIOPHARMACEUTICAL FOR THE THERAPY OF TUMORS OVER-EXPRESSING INTEGRINS A (V) ß (3).

Country Status (1)

Country Link
MX (1) MX345185B (en)

Also Published As

Publication number Publication date
MX2012003632A (en) 2013-09-26

Similar Documents

Publication Publication Date Title
MX2021008977A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer.
MX2017006624A (en) Antibodies against cd73 and uses thereof.
MX2016015176A (en) Site-specific conjugation of linker drugs to antibodies and resulting adcs.
EA201890915A1 (en) CONJUGATES FOR DELIVERY OF MEDICINES AND METHODS OF TREATMENT OF DISEASES CAUSED BY CELLS EXPRESSING PSMA
EA201691023A1 (en) PEPTIDOMIMETIC CONNECTIONS AND THEIR CONJUGATES ANTIBODIES WITH MEDICINE
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
MX2015003772A (en) Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer.
EP2582727A4 (en) Antibodies to endoplasmin and their use
NZ606466A (en) Peptide radiotracer compositions
PH12018500701A1 (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
SG10201810357WA (en) Ly75 as cancer therapeutic and diagnostic target
EP2519542A4 (en) Anti-cdh3 antibodies and uses thereof
SG10201806064XA (en) Anti-tumor compositions and methods
GB201103696D0 (en) Technetium labelled peptides
WO2011119888A3 (en) N-cadherin: target for cancer diagnosis and therapy
MX2015004703A (en) Injectable cancer compositions.
CO6690754A2 (en) Anti-vegfr-3 antibody compositions
MX345185B (en) GOLD NANOPARTICLES RADIOLABELLED WITH 177LU AND CONJUGATED TO PEPTIDES C (RGDFK) C AS A NOVEL RADIOPHARMACEUTICAL FOR THE THERAPY OF TUMORS OVER-EXPRESSING INTEGRINS A (V) ß (3).
MX336321B (en) 99-mtc-tat-bombesin as a novel radiopharmaceutical for the early detection of breast cancer.
MX345184B (en) Gold nanoparticles radiolabelled with 99mtc and conjugated to peptides c [rgdfk(c)] as a novel radiopharmaceutical for the detection in vivo of angiogenesis.
IL261757B1 (en) Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties
MX2014004897A (en) 99MTC-N2S2-TAT(49-57)-C(RGDYK) AS A HYBRID RADIOPHARMACEUTICAL FOR TUMORS EXPRESSING A(V)ß(3) INTEGRINS.
GB201019824D0 (en) Radioiodination method
MX2008009363A (en) Technetium 99-m- oxytocin as a novel radiopharmaceutical for the detection of breast cancer.
PL408191A1 (en) Antineoplastically active and selective system for supplying the doxorubicin drug and method for producing it

Legal Events

Date Code Title Description
FG Grant or registration